Abstract
Neurodegenerative diseases are the sixth leading cause of death in the US. The market for disease-modifying drugs is enormous, but no drug exists. Academic scientists are increasingly pursuing the discovery and development of therapeutics. Their progress could potentially reduce the risk of failure sufficiently to warrant greater industry investment and movement of leads into clinical trials. Here we consider the many obstacles to the development of therapeutics for neurodegenerative disease within academia, with a special focus on organizational issues.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Disease modification and Neuroprotection in neurodegenerative disorders
Translational Neurodegeneration Open Access 26 September 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Alzheimer's Association. Alzheimers Dement. 6, 158–194 (2010).
Centers for Disease Control and Prevention and The Merck Company Foundation. The state of health and aging in America (Merck Company Foundation, Whitehouse Station, New Jersey, USA, 2007).
Alzheimer's Association. Alzheimers Dement. 5, 234–270 (2009).
Ferri, C.P. et al. Lancet 366, 2112–2117 (2005).
Acemoglu, D. & Linn, J. Q. J. Econ. 119, 1049–1090 (2004).
Benedetti, F., Carlino, E. & Pollo, A. Neuropsychopharmacology published online, 10.1038/npp.2010.81 (30 June 2010).
Spiegel, A. The growing power of the sugar pill. National Public Radio <http://www.npr.org/templates/story/story.php?storyId=124367058> (2010).
Hanson, S., Nadig, L. & Altevogt, B. Venture philanthropy strategies to support translational research: workshop summary <http://www.nap.edu/catalog/12558.html> (Forum on Neuroscience and Nervous System Disorders, Institute of Medicine of the National Academies, 2009).
Congressional Budget Office. Research and development in the pharmaceutical industry (US Government Printing Office, 2006).
Cockburn, I.M. & Henderson, R.M. in NBER Innovation Policy and the Economy vol. 1 (eds. Jaffe, A.B., Lerner, J. & Stern, S.) 20–21 (National Bureau of Economic Research, Cambridge, Massachusetts, USA, 2000).
Young, T.A. Int. J. Intellect. Prop. Law Econ. Manage. 1, 13–18 (2005).
National Institutes of Health. Blueprint neurotherapeutics network. NIH Blueprint for Neuroscience Research <http://neuroscienceblueprint.nih.gov/bpdrugs/index.htm> accessed 23 August 2010.
Duggan, M. J. Health Econ. 24, 1–31 (2005).
Lanjouw, J.O. & Cockburn, I.M. World Dev. 29, 265–289 (2001).
Fraser, J. Tomm. Technol. Trans. 1, 9–20 (2009).
Ioannidis, J.P.A. PLoS Clin. Trials 2006, e36 (2006).
Inglese, J. et al. Proc. Natl. Acad. Sci. USA 103, 11473–11478 (2006).
Boettiger, S. & Bennett, A.B. Nat. Biotechnol. 24, 320–323 (2006).
Thursby, J. & Thursby, M. AUTM J. 12, 9–22 <http://www.provendis.info/fileadmin/info/pdfs/1255.pdf> (2000).
Thursby, J., Jensen, R. & Thursby, M. J. Technol. Transf. 26, 59–72 (2001).
Lockett, A. & Wright, M. Res. Policy 34, 1043–1057 (2005).
Friedman, J. & Silberman, J. J. Technol. Transf. 28, 17–30 (2003).
Markman, G., Phan, P., Balkin, D. & Gianiodis, P. J. Technol. Transf. 29, 353–364 (2004).
Lach, S. & Schankerman, M. J. Euro. Econ. Assoc. 2, 252–264 (2004).
Link, A.N. & Siegel, D.S. Eur. J. Finance 11, 169–181 (2005).
DiMasi, J.A., Hansen, R.W. & Grabowski, H.G. J. Health Econ. 22, 151–185 (2003).
Adams, C.P. & Brantner, V.B. Health Aff. 25, 420–428 (2006).
Reinhardt, U.E. Health Aff. 20, 136–149 (2001).
Aisen, P.S. et al. Alzheimers Dement. 6, 239–246 (2010).
Weiner, M.W. et al. Alzheimers Dement. 6, 202–211 (2010).
Anonymous. Economist 395, 81–82 (17 June 2010).
Bynum, J. Characteristics, costs, and health service use for Medicare beneficiaries with a dementia diagnosis. Report 1: Medicare current beneficiary survey (Alzheimer's Association, 2009).
Acknowledgements
This work was supported by the Taube-Koret Center for Huntington's Disease Research, by NIH - National Institute of Neurological Disorders and Stroke grants 2R01 NS039074 and 2R01 NS045091 and NIH - National Institute on Aging grant 2P01 AG022074, and by The J. David Gladstone Institutes. I thank S. Williams, S. Freedman, M. Sutherland, F. Dorey, M. Lopez, L. Bruijn, R. Blumenstein, R. Pacifici, N. Wexler, C. Johnson, C. Austin, L. Vetter, A. Grove, P. Lansbury, T. Reisine, G. Naeve and members of the Finkbeiner laboratory for helpful discussions and/or comments on an early version of this manuscript. I thank G. Howard and S. Ordway for editorial assistance, and K. Nelson for administrative assistance.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Finkbeiner, S. Bridging the Valley of Death of therapeutics for neurodegeneration. Nat Med 16, 1227–1232 (2010). https://doi.org/10.1038/nm.2222
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.2222
This article is cited by
-
Translating Behavior Analysis: a Spectrum Rather than a Road Map
Perspectives on Behavior Science (2018)
-
Disease modification and Neuroprotection in neurodegenerative disorders
Translational Neurodegeneration (2017)
-
Surface-based morphometry reveals caudate subnuclear structural damage in patients with premotor Huntington disease
Brain Imaging and Behavior (2017)
-
Autophagy induction enhances TDP43 turnover and survival in neuronal ALS models
Nature Chemical Biology (2014)
-
Accelerating commercialization: a new model of strategic foundation funding
The Journal of Technology Transfer (2014)